- Home
- VNT vs PCVX Comparison
VNT vs PCVX Comparison
Compare VNT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNT
- PCVX
- Stock Information
- Founded
- VNT 2019
- PCVX 2013
- Country
- VNT United States
- PCVX United States
- Employees
- VNT N/A
- PCVX N/A
- Industry
- VNT Industrial Machinery/Components
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- VNT Industrials
- PCVX Health Care
- Exchange
- VNT Nasdaq
- PCVX Nasdaq
- Market Cap
- VNT 4.4B
- PCVX 4.3B
- IPO Year
- VNT N/A
- PCVX 2020
- Fundamental
- Price
- VNT $34.89
- PCVX $31.45
- Analyst Decision
- VNT Buy
- PCVX Strong Buy
- Analyst Count
- VNT 7
- PCVX 10
- Target Price
- VNT $42.80
- PCVX $136.50
- AVG Volume (30 Days)
- VNT 1.1M
- PCVX 2.3M
- Earning Date
- VNT 05-01-2025
- PCVX 05-07-2025
- Dividend Yield
- VNT 0.28%
- PCVX N/A
- EPS Growth
- VNT N/A
- PCVX N/A
- EPS
- VNT 2.46
- PCVX N/A
- Revenue
- VNT $2,964,300,000.00
- PCVX N/A
- Revenue This Year
- VNT $2.45
- PCVX N/A
- Revenue Next Year
- VNT $4.72
- PCVX N/A
- P/E Ratio
- VNT $13.89
- PCVX N/A
- Revenue Growth
- VNT N/A
- PCVX N/A
- 52 Week Low
- VNT $27.22
- PCVX $27.66
- 52 Week High
- VNT $41.61
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- VNT 69.04
- PCVX 37.17
- Support Level
- VNT $33.06
- PCVX $28.09
- Resistance Level
- VNT $33.95
- PCVX $36.71
- Average True Range (ATR)
- VNT 0.92
- PCVX 2.47
- MACD
- VNT 0.58
- PCVX 1.18
- Stochastic Oscillator
- VNT 92.89
- PCVX 38.98
About VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.